EMEA/H/C/005306Multiple myelomaLenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).

Authorised

yes

2020-12-18

Accord Healthcare S.L.U.

Lenalidomide Accord

lenalidomide

EMEA/H/C/004857Multiple myelomaLenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Authorised

yes

2018-09-20

Bristol-Myers Squibb Pharma EEIG

Revlimid

lenalidomide

EMEA/H/C/000717Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Authorised

2007-06-14

Krka, d.d., Novo mesto

Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)

lenalidomide

EMEA/H/C/005348Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1).Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1).Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Authorised

yes

2021-02-11

Krka, d.d., Novo mesto

Lenalidomide Krka d.d.

lenalidomide

EMEA/H/C/005729Multiple myelomaLenalidomide Krka d.d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Krka d.d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Krka d.d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesLenalidomide Krka d.d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Follicular lymphomaLenalidomide Krka d.d. in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Withdrawn

yes

2021-02-11

Krka, d.d., Novo mesto

Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)

lenalidomide

EMEA/H/C/005734Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Authorised

yes

2021-02-11

>Company

>Drugname

>Inn

>Product Number / Indication

>Status

>Generic

>Biosimilar

>Orphan

>Marketing Authorisation

>Marketing Refusal

Subscribe to access the full database, or Start Trial

Country

Patent Number

Title

Estimated Expiration

African Regional IP Organization (ARIPO)

2324

Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.

⤷ Start Trial

Argentina

047994

FORMAS POLIMORFICAS DE 3-(4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA

⤷ Start Trial

Argentina

057868

METODOS EN LOS QUE SE USA 3-(4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA PARA EL TRATAMIENTO DE CIERTAS LEUCEMIAS

⤷ Start Trial

Argentina

102756

FORMAS POLIMÓRFICAS DE 3-(4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL)-PIPERIDIN-2,6-DIONA Y COMPOSICIONES QUE LAS COMPRENDEN

⤷ Start Trial

Austria

459357

⤷ Start Trial

Austria

531369

⤷ Start Trial

>Country

>Patent Number

>Title

>Estimated Expiration

Subscribe to access the full database, or Start Trial

Patent Number

Supplementary Protection Certificate

SPC Country

SPC Expiration

SPC Description

2105135

5/2015

Austria

⤷ Start Trial

PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805

2105135

Estonia

2105135

Luxembourg

PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805

0925294

07C0056

France

⤷ Start Trial

PRODUCT NAME: LENALIDOMIDE; REGISTRATION NO/DATE: EU/1/07/391/001-004 20070618

2105135

300717

Netherlands

⤷ Start Trial

PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805

2105135

C300717

Netherlands

⤷ Start Trial

PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805

>Patent Number

>Supplementary Protection Certificate

>SPC Country

>SPC Expiration

>SPC Description

Subscribe to access the full database, or Start Trial

Last updated: July 24, 2026

Lenalidomide revenue is driven by sustained uptake in multiple myeloma (MM) and related hematology indications, offset by ongoing erosion from generic entry in key markets and by manufacturing and contract dynamics across major suppliers. Commercial momentum remains supported by combination regimens (notably with dexamethasone and CD38 antibodies) and line-of-therapy expansion. Financial trajectory is shaped by: (1) patent/market-exclusivity roll-off beginning in the late 2020s across select geographies for follow-on products, (2) competitive pricing pressure post-generic launches, (3) supply availability and capacity constraints in active ingredient and finished dose production, and (4) payer and hospital formularies that increasingly steer toward lower-cost versions.

Key takeaways on the risk profile for 2026 and beyond: pricing and margin compression are the dominant near-term financial headwinds, while clinical depth in MM remains the core demand stabilizer. The largest value transfer risk flows through patent and exclusivity expiry for branded formulations and follow-on patents, followed by substitution as generics become procurement standard.

How big is the lenalidomide market and what is the revenue growth trajectory?

Lenalidomide is a high-volume oncology/hematology product with long-running revenue due to broad MM use, including newly diagnosed and relapsed settings. Market growth is less about rapid new patient expansion and more about intensity of regimen use, line-of-therapy placement, and sustained persistence in chronic treatment cycles.

Demand engine

Multiple myeloma remains the primary revenue pool.
Use spans both induction and maintenance in newly diagnosed disease and multiple relapsed settings.
Combination regimens drive unit intensity: lenalidomide paired with dexamethasone and, in later relapses, with CD38-targeting antibodies in practice.

Trajectory shape

Late-cycle branded volume growth is muted; revenue growth typically tracks a mix of (a) patient count, (b) adherence/persistence, and (c) net price.
Post-generic entry, top-line growth becomes price-led rather than volume-led, with margin compression as the dominant financial outcome.

Commercial implication

Companies with manufacturing scale and reliable supply capture volume; companies without competitive unit cost risk share loss when payers tighten formularies.

Indicative KPI set used by market participants

Unit shipments (capsules/tablets) and Rx volume by geography.
Net price and discounting trends.
Share-of-formulary and tender outcomes for generic competitors.
Channel inventory and wholesaler buy-down behavior around contract changes.

What market dynamics drive lenalidomide pricing and procurement decisions?

Lenalidomide pricing and procurement are shaped by aggressive substitution incentives, tender-driven contracting, and continuous price benchmarking across oncology hematology formularies.

1) Tender and formulary substitution

Hospital systems and national tenders increasingly award on lowest net acquisition cost, constrained by supply reliability.
Once a generic is considered interchangeable and available, payer behavior typically shifts quickly because lenalidomide is orally dosed and adherence monitoring does not materially differentiate products.

2) Supply availability and capacity

Active ingredient and finished-dose capacity constrain short-term availability, affecting net revenue timing. When supply tightens, branded or higher-priced suppliers can hold price longer.
When capacity expands, price drops accelerate because procurement shifts to the cheapest dependable source.

3) Contracting and rebates

Oncology hematology contracts often bundle across multiple drugs and can delay substitution even after launch if rebates and performance clauses are favorable.
Generic erosion can be slower where a branded supplier negotiates favorable supply terms and where the product is entrenched with clinicians.

4) Patient out-of-pocket pressure

In markets where patient cost-sharing rises, payer design favors lower-cost alternatives. Substitution often accelerates after formulary changes.

What exclusivity and patent cliffs matter for lenalidomide’s long-term financial outlook?

Lenalidomide has faced multiple waves of exclusivity and patent-related barriers historically, and the long-term financial picture is still dominated by follow-on patent estates tied to specific uses, formulations, dosing regimens, and manufacturing methods.

How the cliff risk works commercially

As generics launch, the branded revenue line typically declines sharply, then stabilizes at a lower plateau when a minority of prescriptions remain branded due to physician preference, payer exceptions, or supply perceptions.
Follow-on patent enforcement delays substitution selectively for particular dosage forms, strengths, or patient subpopulations.

Exclusivity timeline dynamics to monitor

Composition-of-matter coverage for the base compound has long since ceased to be the only driver in most jurisdictions.
Remaining value depends on:
- formulation-specific patents (excipient, coating, stability, manufacturing process)
- method-of-use patents (specific regimens in defined settings)
- pediatric or other regulatory exclusivities where applicable
- patent thickets linked to branded manufacturing and labeling

Featured practical implication for investors and litigators

Revenue erosion tends to correlate less with single patent expiration and more with a synchronized set of expirations that removes both regulatory listing barriers (e.g., Orange Book restrictions in the US) and litigation friction for multiple strengths.

When does lenalidomide lose exclusivity and what does that mean for generic entry risk?

Commercial “when” is determined by a portfolio of US and non-US filings that can block or delay generic substitution per dosage strength and indication-linked labeling. In the US, entry risk is expressed through Paragraph IV challenges and any resultant settlements that create “launch calendars” for each strength.

Entry risk mechanics

Generic entry typically becomes more likely when:
- key Orange Book listings for the marketed strength expire, are found invalid, or are removed via settlement
- litigation reaches final judgment or is resolved by covenant not to sue
- regulatory labeling removes indication-specific restrictions

Financial translation

A settlement that permits early generic launch creates a known revenue step-down.
If generic entry is delayed by court outcomes, branded revenue can remain protected at least for the contested strengths.

What is the Orange Book status of lenalidomide and how does it affect launch timing?

Orange Book listings determine which patents are “listed” against the FDA-approved drug product and, therefore, which are eligible for Paragraph IV challenge. For lenalidomide, the Orange Book is a key gating factor for US generic launch timing at the dosage strength level.

What market participants monitor

Which patents remain listed for each strength.
Whether listed patents are formulation- or method-of-use directed.
Litigation posture for each listed patent family.

Commercial impact

If key listed patents for a strength remain in force or under active litigation protection, generics may be limited to “at-risk” launches only for unprotected indications or strengths. That caps volume capture and slows price erosion.

(Orange Book-specific itemization is not included here because it requires product-specific patent listing extraction by strength and NDA/BLA linkage.)

How many patents cover lenalidomide formulations and methods of use, and where are the gaps?

The lenalidomide patent estate is typically dense due to:

multiple method-of-use patents across line-of-therapy and combinations
formulation and manufacturing patents supporting specific marketed product presentations
continued prosecution and continuation filings

Where gaps usually appear

Non-core patents that claim incremental stability or manufacturing steps often fall first as generic manufacturers can redesign processes.
Some method-of-use patents are narrower and may be avoided by labeling strategy or by shifting treatment away from the claimed regimen in practice.

Financial translation

When patent gaps appear across multiple strengths, competitive substitution accelerates, producing a faster revenue decline than a single expiration would suggest.

Which companies are challenging lenalidomide and what settlement patterns drive revenue erosion?

US generic entry and litigation against lenalidomide has historically involved multiple generics and settlement-driven launch calendars. The market pattern is that settlements typically:

allow a “first generic” launch on specific dates
delay additional challengers through covenants and/or partial blocking
create strength-level step changes rather than a single nationwide wipeout

What to watch for

First-filer launch allowances by strength.
Subsequent entrant timing triggered by remaining patent clearances.
Labeling carve-outs that restrict early substitution to certain indications, though in practice interchangeability still drives purchasing.

(Specific filer names and settlement docket details are excluded here because they require current, case-level extraction.)

How does lenalidomide compare with alternative myeloma agents in market positioning and revenue durability?

Lenalidomide competes within the MM backbone. Its durability comes from:

oral administration
deep placement in both newly diagnosed and relapsed settings
entrenched clinician familiarity and long-standing line-of-therapy integration

Relative advantages

High clinical familiarity and broad regimen compatibility.
Predictable dosing and monitoring workflows.

Competitive pressure

Other regimens may reduce lenalidomide usage intensity in certain patients when toxicity or specific risk factors dominate.
New therapies can shift preference to alternatives where treatment schedules and outcomes are favored, though the core backbone role of lenalidomide has historically remained strong.

Financial impact

Revenue durability remains high, but net pricing compresses most strongly as generics proliferate.

What manufacturing and IP barriers block generic competition for lenalidomide?

Manufacturing and IP barriers typically include:

process-related patents that require redesign, not just sourcing the API
controls around impurities, polymorph form, and stability profiles that are tied to regulatory submissions and validated methods
regulatory quality requirements that can slow entry even when patents are weak

Financial translation

Bottlenecks in GMP scale-up can keep supply limited and allow remaining higher-cost sources to hold share longer.
Where supply is adequate, substitution becomes rapid and margins compress across the value chain.

What is the role of supply chain and API sourcing in lenalidomide revenue outcomes?

Lenalidomide is a global product with supply chains sensitive to:

API sourcing availability
yield, batch acceptance rates, and regulatory compliance
logistics and forecast accuracy due to the chronic nature of treatment

Revenue effect channels

Supply constraints can delay shipments, pushing revenue across quarters.
Quality rejections or batch failures delay commercialization schedules and reduce forecast confidence.

How do payer policies and reimbursement affect lenalidomide financial performance?

Payer pressure increases when:

formularies require step edits favoring lower acquisition costs
oncology drug budgets tighten during fiscal periods
contracting favors tender winners

What stabilizes revenue

Clinician buy-in when clinical outcomes are established for specific regimens.
Patient continuity once a regimen is established, particularly if switching introduces perceived risk, even if substitution is allowed.

Key Takeaways

Lenalidomide’s financial trajectory remains demand-stable due to deep MM regimen placement, but revenue growth is increasingly constrained by net price compression after generic substitution.
Market dynamics are dominated by tender-based procurement, contract structures, and supply reliability rather than by trial-driven demand shocks.
Long-term financial upside depends on how much of the branded and higher-priced share persists through patent or exclusivity structures across strengths and on how fast generic competition expands across those strengths.
The primary risk line is synchronized patent clearance that triggers multiple-strength generic launches, creating faster revenue erosion than single expiration events.
The dominant operational determinant of quarterly outcomes is manufacturing and batch availability, which can shift revenue timing and influence net pricing.

FAQs

What drives lenalidomide net price versus unit volume in the years after generic entry?
Which MM lines of therapy consume the largest share of lenalidomide demand and how does that affect substitution risk?
How do strength-specific patents and Orange Book listings change generic launch calendars for lenalidomide?
What supply chain indicators best predict near-term revenue volatility for lenalidomide manufacturers?
How do reimbursement and hospital tender cycles translate into quarterly shifts in lenalidomide market share?

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Paragraph IV Patent Certifications. U.S. Food and Drug Administration. https://www.fda.gov/

International Patents:	331
US Patents:	2
Tradenames:	2
Applicants:	19
NDAs:	21
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	19
Raw Ingredient (Bulk) Api Vendors:	122
Clinical Trials:	1,236
Patent Applications:	5,828
Drug Prices:	Drug price trends for LENALIDOMIDE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LENALIDOMIDE
What excipients (inactive ingredients) are in LENALIDOMIDE?	LENALIDOMIDE excipients list
DailyMed Link:	LENALIDOMIDE at DailyMed

LENALIDOMIDE - Generic Drug Details

What are the generic sources for lenalidomide and what is the scope of freedom to operate?

Summary for LENALIDOMIDE

Recent Clinical Trials for LENALIDOMIDE

Pharmacology for LENALIDOMIDE

Anatomical Therapeutic Chemical (ATC) Classes for LENALIDOMIDE

Paragraph IV (Patent) Challenges for LENALIDOMIDE

US Patents and Regulatory Information for LENALIDOMIDE

Expired US Patents for LENALIDOMIDE

EU/EMA Drug Approvals for LENALIDOMIDE

International Patents for LENALIDOMIDE

Supplementary Protection Certificates for LENALIDOMIDE

Lenalidomide Market Dynamics and Financial Trajectory (2026): Revenue Drivers, Patent/Exclusivity Overhang, and Generic/Biosimilar Risk

How big is the lenalidomide market and what is the revenue growth trajectory?

What market dynamics drive lenalidomide pricing and procurement decisions?

What exclusivity and patent cliffs matter for lenalidomide’s long-term financial outlook?

When does lenalidomide lose exclusivity and what does that mean for generic entry risk?

What is the Orange Book status of lenalidomide and how does it affect launch timing?

How many patents cover lenalidomide formulations and methods of use, and where are the gaps?

Which companies are challenging lenalidomide and what settlement patterns drive revenue erosion?

How does lenalidomide compare with alternative myeloma agents in market positioning and revenue durability?

What manufacturing and IP barriers block generic competition for lenalidomide?

What is the role of supply chain and API sourcing in lenalidomide revenue outcomes?

How do payer policies and reimbursement affect lenalidomide financial performance?

Key Takeaways

FAQs

References (APA)

Make Better Decisions: Try a trial or see plans & pricing